

The *in vivo* effect of dry hydro-alcoholic extract of *Echinacea purpurea* on angiogenic activity of human blood mononuclear cells

EWA SKOPIŃSKA-RÓŻEWSKA¹, EWA SOMMER¹, BARBARA J. BAŁAN², ADAMINA BOROWSKA³, DOROTA RADOMSKA-LEŚNIEWSKA⁴

¹Department of Pathology, Center for Biostructure Research, Medical University of Warsaw, Poland

²Department of Immunology and Nutrition, Medical University of Warsaw, Poland

³Department of Laboratory Diagnostics and Immunology, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

⁴Department of Histology and Embryology, Center for Biostructure Research, Medical University of Warsaw, Poland

Abstract

The aim of this study was to evaluate the effect of dry hydro-alcoholic extract of *Echinacea purpurea* (IMMUNAL forte), or placebo, administered for seven days to 22 healthy human volunteers in daily dose of one or two tablets, on the angiogenic activity of their blood mononuclear cells (MNC), tested by mice cutaneous test (leukocyte-induced angiogenesis – LIA), and on the number of CD4+ and CD8+ T lymphocytes.

Results: Immunal forte administration resulted in highly statistically significant stimulation of MNC angiogenic activity in both dosage groups and significant increase of CD4/CD8 ratio in persons treated with 2 tablets daily what was connected with significant decrease of CD8+ lymphocytes in their blood. In persons treated with 1 tablet daily both CD8+ and CD4+ lymphocytes significantly increased in number. No stimulatory effect was observed after administration of placebo. All biochemical results were in normal values, and there were no differences between groups.

Key words: *Echinacea purpurea*, human blood mononuclear cells, angiogenesis, T lymphocytes.

(Centr Eur J Immunol 2010; 35 (4): 223-226)

Introduction

Herbal drugs containing *Echinacea purpurea* extracts are commonly used for treatment of upper respiratory tract infections. *Echinacea* extracts contain many compounds with immunomodulatory and anti-inflammatory activity – alkamides, polysaccharides, polyphenols, glycoproteins, essential oils, tannins, and others. Studies in experimental animals have shown that *Echinacea* increases immune response to antigens and may enhance phagocytosis and various lymphocyte activities [1-5].

Previously, we reported stimulatory effect of *Echinacea purpurea* succus stabilized with ethanol (IMMUNAL drops, LEK, Slovenia) on various parameters of human leukocytes activity [6]. However, from experimental studies performed earlier we know that various forms of *Echinacea purpurea* preparations may vary in their immunotropic activity, and some of them were immunosuppressive in doses recom-

mended by producers. So, the aim of the present study was to evaluate the effect of other form of *Echinacea purpurea*, dry hydro-alcoholic extract (IMMUNAL forte tablets), administered for 7 days to healthy human volunteers, on the ability of their blood mononuclear leukocytes to induce neovascular cutaneous response in mice. Counting of CD4+ and CD8+ lymphocytes and some biochemical examinations were also performed.

Material and methods

Study was performed in 22 healthy male volunteers, 20-40 years old. Informed consent was obtained from all persons. All experiments were accepted and supervised by the local Ethical Committee.

Blood from cubital vein was obtained twice, before and after 7 days treatment.

Correspondence: Ewa Skopińska-Różewska, Department of Pathology, Center for Biostructure Research, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw, Poland, e-mail: ewaskop@hotmail.com

The following materials were studied:

- *Echinaceae purpureae* aerial parts dry hydro-alcoholic extract (IMMUNAL forte – tablets, LEK), 160 mg (2 tablets) daily for 7 days – 8 persons,
- IMMUNAL forte 80 mg (1 tablet) daily, for 7 days – 6 persons,
- placebo, 1 tablet daily for 7 days – 8 persons.

Mononuclear cells (MNC) were isolated from heparinised blood on Lymphoprep gradient, washed thrice with phosphate buffered saline (PBS), and resuspended in Parker medium. Cutaneous angiogenesis assay (LIA test) was performed according to Majewski *et al.* [7] with some modifications. Briefly, MNC were injected intradermally into 6-7 weeks old female inbred Balb/c mice (multiple 0.05 ml samples of 5×10^5 cells each, at least 2-4 mice per group). Before performing injections the mice were anaesthetized with 3.6% chloralhydrate (0.1 ml per 10 g of body mass) and both flanks of each mouse were finely shaved with razor blade. On each flank 2-3 injections were localized. In order to facilitate the localization of cell injection sites later on, the suspension was colored with 0.1% of trypan blue. After 72 hours mice were sacrificed with lethal dose of Morbital. All newly formed blood vessels were identified and counted in dissection microscope, on the inner skin surface, at magnification of 6 \times , in 1/3 central area of microscopic field. Identification was based on the fact that new blood vessels, directed to the point of cells injection are thin and/or differ from the background vasculature in their tortuosity and davarications.

Analysis of T lymphocytes was done by monoclonal antibody staining of specific markers CD4 and CD8, using DAKO APAP KIT System 40, USA, in Lymphoprep-isolated blood mononuclear cell suspensions, according to




Fig. 1. Angiogenic activity of human blood mononuclear cells (MNC) before and after 7-days treatment with 2 IMMUNAL tablets, presented as mean number of newly-formed blood vessels, n = number of LIA tests

producer instruction. Triplicate samples were established from each material.

Biochemical studies of volunteers. The following laboratory studies were performed in both placebo and subject groups: number of leukocytes and their subpopulations, prothrombin time, plasma level of fibrinogen, kaolin-kephalinic time, serum concentration of IgG, IgA, IgM, and C3 and C4 fractions of complement.

All samples were analysed using autoanalysers: haematological SYSMEX SF-3000; biochemical HITACHI 911 and BCT (for coagulation system).

Statistical analysis of the results was performed using unpaired t test and a one-way ANOVA. The significance of differences between the groups was verified with a Bonferroni Multiple Comparison post test (GraphPad InStat3).

Results

The results of angiogenic activity of MNC and CD4/CD8 ratio are presented in Fig. 1 and on the table 1 and table 2. IMMUNAL forte administration resulted in highly statistically significant stimulation of MNC angiogenic activity in both dosage groups (the two-tailed p -value is 0.0001, considered extremely significant). Variation among column means is significantly greater than expected by chance. We also found significant increase of CD4/CD8 ratio in persons treated with 2 tablets daily what was connected with significant decrease of CD8+ lymphocytes in their blood. In persons treated with 1 tablet daily both CD8+ and CD4+ lymphocytes significantly increased in number. No stimulatory effect was observed after administration of placebo.

All hematological and biochemical results were in normal values, and there were no differences between groups.

Table 1. The effect of IMMUNAL tablets or placebo administration to human volunteers for 7 days on angiogenic activity of their blood mononuclear cells

	N	Stimulation index \pm SE
IMMUNAL 2 tablets (8 persons)	219	1.24 \pm 0.03
IMMUNAL 1 tablet (6 persons)	172	1.15 \pm 0.02
Placebo (8 persons)	238	1.04 \pm 0.01
Statistical significance of differences from placebo		$p < 0.0001$

*The results are presented as mean stimulation indices (value after treatment / value before treatment); n = total number of LIA tests
Unpaired t test (GraphPad InStat3)
The two-tailed p-value is 0.0001, considered extremely significant.*

Discussion

The modified allogeneic and xenogenic leukocyte-induced angiogenesis tests were introduced by Kaminski *et al.* [8] and used up today in the experimental and clinical studies for evaluation of total reactivity of cells isolated from lymphatic tissues or blood mononuclear leukocytes [9]. Lymphocytes and monocytes, grafted into mice skin, released various cytokines and growth factors important for the development of neovascular response. It was demonstrated in rabbits with experimental hyperlipidemia that their blood lymphocytes express enhanced angiogenic activity, and significant increase of FcGR positive cells was detected [10, 11]. In rats, similar effect was obtained by physical training [12]. *In vivo* exposure of mice to essential oil of *Melaleuca alternifolia* (tea tree) or feeding them *Echinacea purpurea*, *Rhodiola rosea*, *Rhodiola kirilowii*, *Rhodiola quadrifida* or *Panax ginseng* extracts increased angiogenic capability of their spleen cells. Administration of *Centella asiatica*, however, decreased spleen cells angiogenic activity [13-16].

It was shown in further studies in man, that the highest angiogenic activity was expressed by T cells forming rosettes with SRBC and bearing both the receptor for the Fc portion of IgG and a CD4 surface antigen [17, 18]. More detailed studies discovered two subpopulations of highly angiogenic human T lymphocytes: first, CD4+ FcG+ with CD2 receptors sensitive to theophylline, and second, CD4+ FcG- with CD2 receptors resistant to theophylline [19, 20]. High angiogenic activity of activated macrophages was also described [21].

In our present study CD4/CD8 lymphocytes ratio increased significantly in volunteers treated with 2 tablets of Immunal for seven days, and accordingly, MNCs from this group of people exerted the highest angiogenic activity.

Angiogenic activity of human blood mononuclear leukocytes decreased in elderly, in comparison with young adults, but no difference depending on sex was observed [22]. Abnormalities were observed in angiogenic activity of MNCs collected from patients with systemic scleroderma [23, 24]. Lowered angiogenic activity of blood MNCs was also observed in patients with coronary heart disease and some patients with oral candidosis [25].

A lot of studies was performed by our scientific team for evaluation the effect of various natural and synthetic substances on human blood MNCs angiogenic capability. In those studies MNCs were isolated from human blood, grafted intradermally to mice, and tested substances were introduced to recipients orally or subcutaneously, for following three days.

In this test system, several natural drugs and herbal extracts behaved as stimulators of immunological angiogenesis: among them Tolpa peat preparation (TPP), stimulating angiogenic activity of T cells and monocytes, water extracts of *Hypericum perforatum* L and *Melissa*

Table 2. The effect of IMMUNAL tablets or placebo administration to human volunteers for 7 days on CD4+/CD8+ T lymphocytes ratio in their blood

	N	CD4/CD8 ratio ± SE	Statistical significance of differences from "before treatment"
Before treatment (22 persons)	66	1.66 ±0.04	
IMMUNAL 2 tablets (8 persons)	24	2.08 ±0.09	p < 0.001
IMMUNAL 1 tablet (6 persons)	18	1.71 ±0.04	Non significant
Placebo (8 persons)	24	1.37 ±0.05	p < 0.05
Statistical significance of differences from placebo		1 tablet p < 0.05 2 tablets p < 0.001	

officinalis L; ether fraction of poplar leaves water extract and isolated from this fraction phenolic acids: caffeic, gallic, salicylic, ferulic and gentisic. Chlorogenic acid behaved as immunomodulator, it increased angiogenic activity of MNCs collected from healthy donors, and decreased abnormally high angiogenic activity of MNCs collected from the blood of rheumatoid arthritis patients. The same was observed for TPP [26-29].

Echinacea purpurea increased angiogenic activity of MNCs collected from the blood of patients with oral candidosis and from the blood of healthy donors [30].

Conclusion

Stimulation by *Echinacea purpurea* extracts of angiogenic factors release by mononuclear leukocytes opens new fields for application of this drug (ischemic diseases, prolonged repair and healing processes, chronic infections and ulcerations).

References

1. Sokolnicka I, Skopińska-Różewska E, Strzelecka H, et al. (2001): Adaptation of biological tests for estimation of the activity of *Echinacea purpurea* extracts. I. *In vivo* studies. *Terapia IX* 3/2:38-42.
2. Skopińska-Różewska E, Furmanowa M, Guzewska J, et al. (2002): The effect of *Centella asiatica*, *Echinacea purpurea* and *Melaleuca alternifolia* on cellular immunity in mice. *Centr Eur J Immunol* 27:142-146.
3. Bany J, Siwicki AK, Zdanowska D, et al. (2003): *Echinacea purpurea* stimulates cellular immunity and anti-bacterial defense independently of the strain of mice. *Pol J Vet Sci* 6: 3-6.
4. Mishima S, Saito K, Maruyama H, et al. (2004): Antioxidant and immune-enhancing effects of *Echinacea purpurea*. *Bioch Pharm Bull* 27: 1004-1009.

5. Hwang SA, Dasgupta A, Actor JK (2004): Cytokine production by non-adherent mouse splenocyte cultures to *Echinacea* extracts. *Clin Chim Acta* 343: 161-166.
6. Skopińska-Różewska E, Sokolnicka I, Radomska-Leśniewska D, et al. (2003): The *in vivo* effect of *Echinacea purpurea* succus on various functions of human blood leukocytes. *Centr Eur J Immunol* 28: 126-130.
7. Majewski S, Skopińska-Różewska E, Jabłońska S, et al. (1985): Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. *Arthritis Rheum* 28: 1133-1139.
8. Kamiński M, Kamińska G, Majewski S (1979): Local graft-versus-host reaction in mice evoked by Peyer's patch and other lymphoid tissue cells tested in a lymphocyte-induced angiogenesis assay. *Folia Biol (Praha)* 24: 104-110.
9. Skopinska-Różewska E, Skopiński P (2001): Modulation of angiogenesis - new field of clinical immunology. *Terapia IX* 3(2): 3-6.
10. Polakowski IJ, Wróblewski T, Fijalkowska A, et al. (1985): The effect of experimental hyperlipidemia on the angiogenic activity of rabbit peripheral blood lymphocytes. *Arch Immunol Ther Exper* 33: 837-840.
11. Skopińska-Różewska E, Wróblewski T, Mościcka-Wesołowska M, et al. (1985): Differential effects of experimental hyperlipidemia on various types of rabbit peripheral blood lymphocyte receptors. *Mech Ageing Develop* 29: 111-116.
12. Polakowski IJ, Skopinska-Różewska E, Nazar K, et al. (1989): Effect of endurance and "sprint" physical training on lymphocyte-induced angiogenesis in rats. *Folia Biol (Praha)* 35: 45-49.
13. Skopińska-Różewska E (2009): Immunotropic and anti-tumor effects of plant adaptogens. I. *Panax ginseng*. *Centr Eur J Immunol* 34: 207-211.
14. Siwicki AK, Skopinska-Różewska E, Hartwich M, et al. (2007): The influence of *Rhodiola rosea* extracts on non-specific and specific cellular immunity in pigs, rats and mice. *Centr Eur J Immunol* 32: 84-91.
15. Skopińska-Różewska EW, Wójcik R, Siwicki AK, et al. (2008): The effect of *Rhodiola quadrifida* extracts on cellular immunity in mice and rats. *Pol J Vet Sci* 11: 105-111.
16. Wójcik R, Siwicki AK, Skopińska-Różewska E, et al. (2009): The effect of Chinese medicinal herb *Rhodiola kirilowii* extracts on cellular immunity in mice and rats. *Pol J Vet Sci* 12: 399-405.
17. Kamiński MJ, Nowaczyk M, Skopińska-Różewska E, et al. (1981): Human peripheral blood T - lymphocyte subpopulations isolated on the basis of their affinity to sheep red blood cells differ in angiogenesis-inducing capability. *Clin Exp Immunol* 46: 327-331.
18. Polakowski IJ, Żukowska M, Włodarska B, et al. (1988): A contribution to studies on the mechanism of lymphocyte-induced angiogenesis: human peripheral blood mononuclear leukocytes with highest angiogenic activity. *Folia Biol (Praha)* 34: 350-355.
19. Skopińska-Różewska E, Ettenger RB, Plaeger-Marshall S, et al. (1988): Surface antigens of theophylline-resistant and theophylline-sensitive human E rosette - forming T lymphocytes. *Folia Biol* 34: 58-62.
20. Żukowska M, Skopińska-Różewska E, Mierzwińska-Nastalska E (2001): Role of the theophylline resistant and theophylline sensitive T lymphocytes in angiogenesis. *Terapia IX* 3(2): 16-17.
21. Polverini PJ, Cotran RS, Gimbrone MA Jr, Unanue ER (1977): Activated macrophages induce vascular proliferation. *Nature* 269: 804-806.
22. Polakowski IJ, Skopińska-Różewska E, Wróblewski T, Pawliszka M (1987): Angiogenesis induced by human peripheral blood lymphocytes: studies on the effect of donors' age and sex on reaction intensity. *Pol Tyg Lek XLII*: 595-596.
23. Kamiński MJ, Majewski S, Jabłońska S, Pawliszka M (1984): Lowered angiogenic capability of peripheral blood lymphocytes in progressive systemic sclerosis (scleroderma). *J Invest Dermatol* 82: 239-243.
24. Marczał M, Majewski S, Skopińska-Różewska E, et al. (1986): Enhanced angiogenic capability of monocyte-enriched mononuclear cell suspensions from patients with systemic scleroderma. *J Invest Dermatol* 86: 355-358.
25. Skopińska-Różewska E, Polakowski IJ, Żukowska M, et al. (1993): The effect of Tolpa peat preparation (TPP) on human mononuclear leukocytes induced angiogenesis. *Herba Polonica* 39: 41-48.
26. Skopińska-Różewska E, Rządkowska-Bodalska H, Olechnowicz-Stępień W, et al. (1991): Effect of extracts of *Hypericum perforatum* L and *Melissa officinalis* L. herbs on local GVH reaction and production of anti-SRBC antibodies. *Bull Pol Acad Sci* 39: 257-266.
27. Sokolnicka I, Glinkowska G, Strzelecka H, et al. (1994): Immunostimulatory effects of water-soluble extracts of poplar buds and leaves and their polyphenolic compounds. *Int J Immunother* 10: 83-88.
28. Glinkowska G, Bałan BJ, Sommer E, et al. (1997): The effect of phenolic compounds of poplar leaves extract on cutaneous angiogenesis reaction induced in mice by human mononuclear leukocytes. *Acta Pol Pharm* 54: 151-154.
29. Skopińska-Różewska E, Strzelecka H, Sommer E, et al. (1994): Influence of some phenolic acids on the angiogenic activity of mononuclear leukocytes isolated from the blood of healthy people and rheumatoid arthritis patients. *Reumatologia* 32: 235-237.
30. Mierzwińska-Nastalska E, Demkow U, Siwicki AK, et al. (2005): The effect of *Echinacea purpurea* extract Echinapur on the angiogenic and chemokinetic activity of human leukocytes. *Pol J Environm Studies* 14 (suppl 2): 639-642.